HCR — Health Issues
Health care quality; physician and hospital quality; health care innovation; Patient Protection and Affordable Care Act/health care reform implementation; unique device identifier policy and post-market surveillance for medical devices; clinical trial design; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, FDA, HRSA and the Childrens Hospital Graduate Medical Education payment program, the Prevention & Public Health Fund, medical research, and prevention; research and scholarly communication policy; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; artificial intelligence/machine learning; algorithm transparency; health disparities; reduction/oversight of prior authorization and other administrative burdens; digital health; Sect. 1557 Nondiscrimination in Health Programs and Activities; cardiomyopathy education and awareness; peripheral arterial disease (PAD) education and awareness; VA Mission Act implementation; COVID-19 and implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, the Families First Coronavirus Response Act , the Coronavirus Aid, Relief, and Economic Security Act, Coronavirus Provider Protection Act, and clinician mental health and wellbeing; patient identification; Pandemic and All Hazards Preparedness; MCIT/TCET/Breakthrough devices; Amputation Reduction and Compassion (ARC) Act (H.R. 307); Resident Education Deferred Interest (REDI) Act (H.R. 2028/S. 942); Implementation and funding for the Cardiomyopathy Health, Education, Awareness, Research and Training in Schools (HEARTS) Act (P.L. 118-176); provide AEDs in transportation facilities with the Public Access to Defibrillation in Transportation Facilities Act (H.R. 5897); Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266; Physician Led and Rural Access to Access to Quality Care Act (H.R. 2191/S. 1390); Section 232, National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; and to protect health care workers from violence with the Save Healthcare Workers Act (H.R. 3178/S. 1600).
Government entities lobbied: Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Office of Management & Budget (OMB); SENATE; White House Office
MMM — Medicare/Medicaid
The One Big Beautiful Bill Act, H.R. 1; Medicare physician payment including, the Medicare Patient Access and Practice Stabilization Act (H.R. 879); the Strengthening Medicare for Patients and Providers Act (H.R. 6160), the Provider Reimbursement Stability Act (S. 4935); the Provider Reimbursement Stability Act (H.R. 8163); and the Efficiency Adjustment Delay Act (H.R. 7520); new/alternative payment models; Medicare coverage, hospital payment of cardiovascular services; access to Medicare claims data; physician and hospital quality; Quality Payment Program; clinical data registries; health care quality; medical imaging and prior authorization; the Stark Law and the in-office ancillary services exception; Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; graduate medical education policy including the Resident Physician Shortage Reduction Act (H.R. 3890/S. 2439); provide a specialty physician loan repayment program with the SPARC Act (H.R 4681/S. 1380); provide deferred interest payments for residents on student loans with the Resident Education Deferred Interest (REDI) Act (H.R. 2028/S. 942); oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; physician-owned hospital policy including the Physician Led Rural Access to Quality Care Act (H.R. 2191/S. 1390) and the Patient Access to Higher Quality Health Care Act (H.R. 4002); COVID-19 public health emergency and the implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, the Families First Coronavirus Response Act, the Coronavirus Aid, Relief, and Economic Security Act; implementation of the Protecting Medicare and American Farmers from Sequester Cuts Act; Increasing Access to Quality Cardiac Rehabilitation Care Act; the expansion of telehealth services, including the CONNECT for Health Act (H.R. 41894206/S. 1261), the Sustainable Cardiopulmonary Rehabilitation Services in the Home At (H.R. 783/S. 248), and the Telehealth Modernization Act (H.R. 5081/S. 2709); Improving maternal health, including Connected Maternal Online Monitoring Act (Connected MOM Act) (H.R. 4977/S. 141), Preventing Maternal Deaths Reauthorization Act of 2025 (H.R. 1909), and Rural Obstetrics Readiness Act (H.R. 1254/S. 380), and the Womens Heart Health Expansion Act (H.R. 7417/S. 3944) ; prior authorization reform, including the Improving Seniors Timely Access to Care Act (H.R. 3514/S. 1816), the Reducing Medically Unnecessary Delays in Care Act (H.R. 2433), and the Safe Step Act (H.R. 5509/S. 2903); clinician-led registry access to federal claims data, including the Access to Claims Data Act (H.R. 4331); and expanding in home prescribing coverage provided in the Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025 (H.R. 6894/S. 717), Centers for Medicare and Medicaid Innovation payment models.
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Office of Management & Budget (OMB); SENATE
TOB — Tobacco
Tobacco use prevention and smoking cessation; FDA regulation of tobacco; electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations; Federal funding for the CDCs Office of Smoking and Health and chronic disease prevention.
Government entities lobbied: Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE